Search Results
Your search for Staff matches 6663 pages
Showing 501 - 550Predicting Ovarian Cancer Relapse With Spatial Tissue Analysis
Researchers have found that spatial tissue analysis may help predict early posttreatment relapse and illuminate new potential therapies in patients with high-grade serous ovarian carcinoma, according to a recent study published by Xu et al in Science Advances. Background Many patients with...
Chemohormonal Therapy for Locally Advanced Prostate Cancer
A neoadjuvant chemohormonal therapy combination may offer extended control of prostate-specific antigen (PSA) levels in patients with locally advanced prostate cancer compared with hormonal therapy alone, according to a recent study published by Qian et al in The Journal of Urology. Background...
Propofol-Based Anesthesia May Offer Improved Detection of Serrated Polyps During Colonoscopy
Deeper sedation with the anesthetic drug propofol may improve detection of serrated polyps in patients undergoing colonoscopy to screen for colorectal cancer, according to a recent study published by Quaye et al in Anesthesiology. Background Nearly all colorectal cancers start as polyps....
Observing a Healthy Diet May Reduce Risk of Cardiovascular Disease in Breast Cancer Survivors
Following a healthy diet may reduce the risk of cardiovascular disease in female breast cancer survivors, according to a recent study published by Ergas et al in JNCI Cancer Spectrum. Background Cardiovascular disease is one of the leading causes of non–breast cancer–related mortality among...
Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer
On April 18, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor alectinib (Alecensa) for adjuvant treatment after tumor resection in patients with ALK-positive non–small cell lung cancer (NSCLC), as detected by an FDA-approved test. Alectinib is an orally...
Novel SPECT/CT Imaging Technique Under Study in Prostate Cancer
A novel single-photon emission computed tomography/computed tomography (SPECT/CT) acquisition method using lead (Pb)-212–prostate-specific membrane antigen (PSMA)-based targeted alpha therapy may provide convenient detection of radiopharmaceutical biodistribution and could lead to improved practice ...
Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC
The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, the Pulmonary Pathology Society, the Association for Molecular Pathology, and the LUNGevity Foundation have developed evidence-based recommendations on the use of certain...
Improving Early Detection of Pancreatic Cancer in High-Risk Patients
Researchers have identified a novel strategy to screen for pancreatic cancer in high-risk patients, according to a recent study published by Zogopoulos et al in JNCCN–Journal of the National Comprehensive Cancer Network. The findings demonstrated the feasibility of improving the early detection and ...
Survival Rates in Patients With Cancer and Intellectual and Developmental Disabilities
Investigators have found a higher rate of mortality among patients with intellectual and developmental disabilities diagnosed with breast cancer, colorectal cancer, or lung cancer, according to a recent study published by Hansford et al in the Canadian Journal of Public Health. Study Methods and...
Natalie S. Callander, MD, on Multiple Myeloma: Management Updates
Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses advances in the treatment of patients with multiple myeloma, including her commentary on smoldering disease, the early use of CAR T-cell therapy, quadruplet therapy, and the use of multiple lines of treatment...
William J. Gradishar, MD, on HR-Positive, HER2-Negative Breast Cancer: Management Update
William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, details the fundamental shift in how clinicians now treat patients with endocrine-sensitive breast cancer, both advanced and early stage, by pairing antihormonal therapy with targeted treatment.
Sophia McKinley, MD, EdM, on Cutaneous Melanoma: Outcomes With Adjuvant Immunotherapy
Sophia McKinley, MD, EdM, of Massachusetts General Hospital, discusses patterns of recurrence in patients with resected cutaneous melanoma during or after adjuvant immunotherapy. She identifies the risk factors associated with overall survival and treatment failure (Abstract 60).
Immunotherapy Resistance and Response to Adoptive Therapy in Patients With Metastatic Uveal Melanoma
Researchers may have uncovered the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in metastatic uveal melanoma, according to a recent study published by Leonard-Murali et al in Nature Communications. The findings demonstrated the potential to...
The Lancet Commission on Breast Cancer: Reducing Overlooked Inequities in Breast Cancer
Investigators have uncovered persistent inequities in breast cancer that may systematically leave many patients behind in spite of recent improvements in research, treatment, and survival, according to a recent report from The Lancet Breast Cancer Commission. These findings were published by Coles...
New Findings Suggest No Correlation Between GLP-1 Receptor Agonists and Thyroid Cancer Risk
Glucagon-like peptide (GLP)-1 receptor agonists may not be associated with an increased risk of thyroid cancer, according to a recent study published by Pasternak et al in the BMJ. Background GLP-1 receptor agonists are designed to reduce blood sugar levels and appetite. They have become...
Study Identifies Genetic Variants Potentially Linked to Prevalent or Persistent HPV Infections
Investigators have uncovered genetic variants that may predispose certain female patients to prevalent or persistent human papillomavirus (HPV) infections and increase their risk of developing cervical cancer, according to a recent study published by Adebamowo et al in the European Journal of Human ...
Illuminating a Potential Culprit in Melanoma Treatment Resistance
Researchers may have uncovered the mechanisms behind the development of targeted therapy resistance in melanoma, according to a recent study published by Aya Moreno et al in Cell Reports. Background The global incidence of melanoma—the deadliest type of skin cancer—is rising, making novel...
Radon Gas Exposure May Be Linked to Increased Incidence of Lung Cancer in Nonsmokers
Long-term exposure to radon gas may be associated with a rise in nonsmoking lung cancer cases, according to a recent consumer survey conducted on behalf of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James)....
Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer
Researchers have found that a novel urine biomarker test may effectively halve the number of cystoscopies necessary in high-risk patients with bladder cancer, according to recent findings presented by Dreyer et al at the European Association of Urology (EAU) Congress 2024. The research also...
Longer Interval May Be Safe for Prostate Cancer Screening in Low-Risk Patients
Undergoing a prostate-specific antigen (PSA) blood test every 5 years may be adequate for screening low-risk men for prostate cancer, according to recent findings presented by Albers et al at the European Association of Urology (EAU) Congress 2024 and simultaneously published in European Urology....
The Lancet Commission on Prostate Cancer: Strategies to Prepare for Predicted Increases in Disease Burden by 2040
Investigators have projected impending increases in the incidence and mortality rates of prostate cancer—especially among individuals in low- and middle-income countries—and proposed new strategies to improve screening, awareness, research diversification, and treatment in a recent The Lancet...
Jenny H. Chang, MD, on New Findings on Merkel Cell Carcinoma and Neoadjuvant Immunotherapy
Jenny H. Chang, MD, of the Cleveland Clinic, discusses the current surgical and radiologic treatment paradigm for patients with stage III Merkel cell carcinoma and the potential for neoadjuvant immunotherapy to help manage the disease and regional lymph node metastases (Abstract 67).
Educational Videos May Encourage Prostate Cancer Screening Among Black Patients
Use of culturally sensitive educational videos may boost knowledge and decrease uncertainty regarding prostate cancer and screening among Black individuals, according to new findings presented by Jones et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract...
BAP1 Mutations May Increase Susceptibility to Asbestos-Induced Malignant Mesothelioma
Researchers have shown that even minimal exposure to chrysotile asbestos may increase susceptibility to the development of malignant mesothelioma in mice with BAP1 germline mutations, according to new findings presented by Kadariya et al at the American Association for Cancer Research (AACR) Annual ...
Ana Oaknin, MD, PhD, on Recurrent Cervical Cancer: New Findings on Atezolizumab, Bevacizumab, and Chemotherapy
Ana Oaknin, MD, PhD, of Spain’s Vall d’Hebron University Hospital, discusses phase III findings from the BEATcc trial, showing that adding atezolizumab to a standard bevacizumab-plus-platinum regimen for patients with metastatic, persistent, or recurrent cervical cancer significantly improves...
An Exosome-Based Liquid Biopsy for Early Detection of Pancreatic Cancer
An investigational exosome-based liquid biopsy accurately detected 97% of stage I to II pancreatic cancers when combined with the biomarker CA 19-9, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract 3899). “Pancreatic cancer is one...
Proteogenomic Signatures May Help Identify Risk of Prostate Cancer Progression in Certain Populations
Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated with higher risk of metastasis and/or recurrence of the disease, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract...
AACR Inaugurates New Leadership
The members of the American Association for Cancer Research (AACR) elected a new 2024 to 2025 President and President-Elect at the AACR’s Annual Business Meeting of Members during the AACR Annual Meeting 2024 in San Diego. New President The AACR welcomed Patricia M. LoRusso, DO, PhD (hc), FAACR, as ...
PARP1-Selective Inhibitor in HRR-Deficient Breast Cancer
The novel poly-ADP ribose polymerase-1 (PARP1)-selective inhibitor saruparib demonstrated early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancer, according to new findings presented by Yap et al at the American Association for...
Investigational Personalized Vaccine in Resected Head and Neck Cancers
TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected human papillomavirus (HPV)-negative head and neck squamous cell cancer (HNSCC), according to results reported at the American Association...
ATM Kinase Inhibitor Plus Radiotherapy for Patients With Glioblastoma
AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in patients with both recurrent and newly diagnosed glioblastoma when given in combination with standard-of-care radiotherapy and showed preliminary efficacy in patients with recurrent...
Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer
The combination of the KRAS G12C inhibitor adagrasib and the anti-EGFR antibody cetuximab showed clinical activity and promising survival outcomes in a cohort of patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer, according to results from the phase I/II KRYSTAL-1...
Biologic Drug-Device Combination Immunotherapy in Metastatic Prostate Cancer
SYNC-T—an investigational therapy that combines a device-induced vaccination at the tumor site with an intratumoral infusion of a multitarget biologic drug—led to numerous clinical responses in patients with metastatic castration-resistant prostate cancer, according to results reported at the...
Immune Response to Investigational RNA Vaccine for Pancreatic Cancer Continues to Correlate With Clinical Benefit
An adjuvant treatment regimen that included autogene cevumeran, an investigational individualized neoantigen-specific mRNA vaccine, induced durable and functional T-cell responses that were associated with a reduced risk of disease recurrence in certain patients with resectable pancreatic cancer,...
Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status
The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer—including those with PD-L1–low tumors—compared with...
RP1 Immunotherapy in Solid Organ Transplant Recipients With Skin Cancer
A novel oncolytic immunotherapy may show antitumor activity in solid organ transplant recipients with skin cancer, according to new findings presented by Migden et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT003). Background "Organ transplant recipients ...
Novel CAR T-Cell Therapy May Show Benefit in Patients With Advanced Clear Cell Renal Cell Carcinoma
The CD70-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy CTX130 may be effective in patients with advanced clear cell renal cell carcinoma, according to findings presented by Srour et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT002)...
Ciltacabtagene Autoleucel and Idecabtagene Vicleucel Approved by the FDA for Pretreated Patients With Multiple Myeloma
On April 5, the U.S. Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (Carvykti) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and...
Mirvetuximab Soravtansine Plus Pembrolizumab in Patients With Endometrial Cancer Subtype
The combination of the antibody-drug conjugate mirvetuximab soravtansine-gynx and the immune checkpoint inhibitor pembrolizumab showed notable activity in patients with recurrent or persistent microsatellite-stable endometrial cancer, according to new findings presented by Porter et al at the...
Can a Personalized Antitumor Vaccine Plus Pembrolizumab Improve Outcomes in Hepatocellular Carcinoma?
Adding a personalized antitumor vaccine to the PD-1 inhibitor pembrolizumab may be safe and about twice as effective at shrinking tumors in patients with hepatocellular carcinoma compared with pembrolizumab alone, according to new findings presented by Yarchoan et al at the American Association for ...
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors
On April 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no...
Judy C. Boughey, MD, on De-escalating Axillary Surgery After Chemotherapy for Breast Cancer
Judy C. Boughey, MD, of the Mayo Clinic, discusses findings from the I-SPY2 trial, which show that although the extent of residual disease and tumor biology in patients with breast cancer may impact outcomes, the type of axillary surgery after neoadjuvant chemotherapy does not (Abstract 3).
Improving Adjuvant Treatment in Patients With Muscle-Invasive Urothelial Carcinoma
Two recent studies have offered new insights into the treatment of muscle-invasive urothelial carcinoma following cystectomy, according to findings presented by Powles et al and Galsky et al at the European Association of Urology Congress 2024. The research could allow physicians to target...
Distinct Microbial Signature Uncovered in KRAS-Mutated Colorectal Cancer
Researchers have identified microbiota signatures that are associated with KRAS mutations in patients with colorectal cancer, according to a recent study published by Huang et al in Microbiology Spectrum. The findings suggest that gut microbes may serve as a noninvasive biomarker for subtypes of...
American Cancer Society Releases Latest Global Cancer Statistics; Cancer Cases Expected to Rise to 35 Million Worldwide by 2050
The American Cancer Society (ACS) has released Global Cancer Statistics 2022, an update of the organization’s report on global cancer facts and trends. According to the findings, an estimated 20 million cancer cases were newly diagnosed in 2022 and 9.7 million people died from the disease...
Danicopan Approved as Add-On Therapy to Ravulizumab or Eculizumab for Extravascular Hemolysis in Adults With Paroxysmal Nocturnal Hemoglobinuria
On April 1, danicopan (Voydeya) was approved by the U.S. Food and Drug Administration (FDA) as add-on therapy to ravulizumab-cwvz or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). VOYDEYA is a first-in-class, oral, Factor D...
Akhil G. Pachimatla, MD, on NSCLC: A Link Between Image-Based Measures of Obesity and Metabolic Pathways
Akhil G. Pachimatla, MD, of Roswell Park Comprehensive Cancer Center, discusses study findings showing that, in patients with non–small cell lung cancer (NSCLC), image-based adiposity measures show stronger correlations with gene-expression changes in these tumors than body mass index measures. Dr. ...
Kerollos N. Wanis, MD, PhD, on Risks for BRCA Mutation Carriers Treated With Breast-Conserving Therapy
Kerollos N. Wanis, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses a study in which he evaluated the risk of future ipsilateral and contralateral breast cancer events in a large cohort of patients with BRCA1 or BRCA2 mutations who chose breast conservation (Abstract 12).
Feasibility of Ending Specialist Follow-up in Patients With Low-Risk CLL
A study published by Brieghel et al in Blood Advances showed that among patients in Denmark who had slow-growing chronic lymphocytic leukemia (CLL) with no symptoms and a low risk for ever needing treatment, those who stopped seeing their doctors for specialized follow-up had fewer hospital visits, ...
Study Examines Shared Decision-Making Policies and Practices Around Lung Cancer Screening
A Medicare policy requiring shared decision-making between primary care physicians and patients regarding whether to proceed with lung cancer screening may require further examination, according to a recent study published by Kale et al in the Annals of Family Medicine. The findings indicated that...
